Companion Animal Pharmaceuticals Market Report 2025

The companion animal pharmaceuticals market size has grown strongly in recent years. It will grow from $16.49 billion in 2024 to $17.9 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to humanization of pets, preventive healthcare measures, rise in pet insurance, changing lifestyle and urbanization, zoonotic disease concerns, zoonotic disease concerns, veterinary healthcare accessibility.

The companion animal pharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $26.52 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to personalized medicine for pets, telehealth and remote veterinary services, focus on nutrition and nutraceuticals, one health initiatives, expansion of veterinary diagnostic services. Major trends in the forecast period include advancements in veterinary medicine, specialized therapeutics for aging pets, regulatory compliance and safety standards, collaborations and partnerships.

The rising incidence of zoonotic diseases is anticipated to drive growth in the companion animal pharmaceuticals market. Zoonotic illnesses, capable of transmission between vertebrate animals and humans, present a considerable public health challenge. In response, the pharmaceutical industry is deploying modern strategies aligned with health principles to combat these diseases and reduce transmission risks. A December 2022 report by the European Centre for Disease Prevention and Control underscores the increasing prevalence of Campylobacteriosis and other zoonotic diseases, highlighting the need for pharmaceutical interventions.

The companion animal pharmaceutical market is poised for growth, fueled by an upsurge in pet ownership. Pet ownership, signifying the human assumption of responsibility for animal care, is on the rise. The market benefits from an expanding pet owner base and a growing recognition of the importance of preventive measures, diagnostics, and treatments for companion animal health. A report from the American Veterinary Medical Association in October 2022 reveals a substantial increase in families owning at least one cat. The trend, supported by increased veterinary spending, underscores the market's growth potential.

The adoption of big data technologies is a noteworthy trend in the companion animal pharmaceuticals sector. Leading companies are actively developing technological solutions to fortify their market positions. Notably, Elanco Animal Health Incorporated and Ginkgo Bioworks launched BiomEdit in April 2022. This microbiome innovation company focuses on developing novel probiotics and related animal pharmaceuticals. The initiative extends to areas such as medicated feed ingredients, nutritional health, therapies for livestock and pets, and biosecurity technologies for monitoring animal illnesses.

Major companies in the companion animal pharmaceutical market are introducing innovative products, such as oral flea and tick treatments, to expand their customer bases, boost sales, and enhance revenue. Oral flea and tick products are medications administered orally to prevent or treat infestations in pets. For example, in October 2024, Elanco Animal Health Incorporated, a US-based pharmaceutical firm, received FDA approval for Credelio Quattro, a new chewable parasiticide formulated for dogs. This product provides monthly protection against six types of parasites, including fleas, ticks, and various internal worms. With the launch of Credelio Quattro, Elanco aims to offer a convenient, comprehensive solution for pet owners seeking broad-spectrum parasite control. This introduction underscores Elanco's commitment to addressing the rising demand for innovative and effective pet health solutions.

In July 2022, Dechra Pharmaceuticals completed the acquisition of Piedmont Animal Health for $210 million. This strategic move enhances Dechra's product portfolio for European and North American markets and augments its scientific and regulatory capabilities. Piedmont Animal Health, a US-based company specializing in companion animal pharmaceuticals, brings complementary offerings to further strengthen Dechra's position in the industry.

Major companies operating in the companion animal pharmaceuticals market are Elanco Animal Health Incorporated, Boehringer Ingelheim International GmbH, Ceva Santé Animale, Chanelle Pharma, Eco Animal Health Group PLC, Ashish Life Science Pvt. Ltd., Endovac Animal Health, Hipra Laboratories, Indian Immunologicals Ltd., Inovet Group, Kyoritsu Seiyaku Corporation, Lutim Pharma Pvt. Ltd., Merck & Co. Inc., Norbrook Laboratories Ltd., Tianjin Ringpu Bio-Technology Co. Ltd., Vetoquinol S.A., Virbac S.A., Zoetis Inc., Agrolabo S.p.A., ALS Pvt. Ltd., Zydus Animal Health and Investments Limited, Eli Lilly and Company, IDEXX Laboratories Inc., Merial Limited, Novartis Animal Health Inc., Dechra Pharmaceuticals PLC, Aratana Therapeutics Inc., Phibro Animal Health Corporation, Kindred Biosciences Inc., Jaguar Health Inc., Nexvet Biopharma PLC, Sentinel Biomedical Inc., PetMed Express Inc., Neogen Corporation, Heska Corporation, Synbiotics Corporation, Eurovet Animal Health B.V., Vironova AB, Abaxis Inc., Bioiberica S.A.U., Putney Inc., Lohmann Animal Health International.

North America was the largest region in the companion animal pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the companion animal pharmaceuticals market report during the forecast period. The regions covered in the companion animal pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the companion animal pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Companion animal pharmaceuticals involve the pharmaceutical medication process where animal pharmacists recommend medications, fill prescriptions, and manage drug therapies for animals. It is utilized in the diagnosis, mitigation, and treatment of various diseases in animals.

The main types of companion animal pharmaceuticals include medications for dogs, cats, horses, and other companion animals. Dogs are highly variable carnivorous domesticated mammals closely related to the common wolf. The indications for these pharmaceuticals cover infectious diseases, dermatologic diseases, pain management, orthopedic diseases, behavioral issues, and other conditions. These medications are typically sold through various distribution channels such as veterinary hospitals, veterinary clinics, and retail pharmacies.

The companion animal pharmaceuticals market research report is one of a series of new reports that provides companion animal pharmaceuticals market statistics, including companion animal pharmaceuticals industry global market size, regional shares, competitors with a companion animal pharmaceuticals market share, detailed companion animal pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the companion animal pharmaceuticals industry. This companion animal pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The companion animal pharmaceuticals market includes revenues earned by entities by providing veterinary pharmaceuticals, vaccines, and health management tools. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.